• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Renal Association-European Dialysis and Transplant Association congress (ERA-EDTA) 2022

May 19 - 22, 2022

  1. Dapagliflozin (Forxiga)
  2. Roxadustat
  3. Sodium zirconium cyclosilicate (Lokelma)
  4. REVEAL-CKD
  5. Eculizumab (Soliris)

HTML

Effects of dapagliflozin in patients with chronic kidney disease according to background angiotensin-converting enzyme inhibitor and angiotensin receptor blocker dose

HTML

DAPA-CKD patient profile: transposability assessment in real-life through the CKD-REIN French cohort

HTML

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents for Treatment of Anemia in Patients With Chronic Kidney Disease Incident to or Not Receiving Dialysis: Pooled Analysis of Four Phase 3 Studies

HTML

A Randomised Controlled Trial of Sodium Zirconium Cyclosilicate versus Standard of Care for Hyperkalaemia in Chronic Kidney Disease: Phase 4 CONTINUITY Study Design and Rationale

HTML

A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin

HTML

Population pharmacodynamic dose-response analysis of serum potassium following dosing with sodium zirconium cyclosilicate

HTML

Healthy plant-based diet for patients with chronic kidney disease (CKD) through use of sodium zirconium cyclosilicate (SZC): A feasibility study (HELPFUL)

HTML

REVEAL-CKD: prevalence of undiagnosed stage 3 chronic kidney disease in Italy

HTML

Long-term outcomes in eculizumab-treated kidney transplant patients enrolled in the global atypical Haemolytic Uraemic Syndrome Registry

HTML

Eculizumab for adult patients with atypical haemolytic-uremic syndrome: Full dataset analysis of post-marketing surveillance in Japan

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice